with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005 Jan 01;23(1):175-83. \[[PubMed: 15625371](https://pubmed.ncbi.nlm.nih.gov/15625371)\] 43. D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec;7(12):1815-1822. \[[PubMed: 23154553](https://pubmed.ncbi.nlm.nih.gov/23154553)\] 44. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P., International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol. 2008 May;3(5):457-66. \[[PubMed: 18448996](https://pubmed.ncbi.nlm.nih.gov/18448996)\] 45. Tammem√§gi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, Commins J, Berg CD. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014 Dec;11(12):e1001764. \[[PMC free article: PMC4251899](/pmc/articles/PMC4251899/)\] \[[PubMed: 25460915](https://pubmed.ncbi.nlm.nih.gov/25460915)\] 46. US Preventive Services Task Force. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Landefeld CS, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021 Mar 09;325(10):962-970. \[[PubMed: 33687470](https://pubmed.ncbi.nlm.nih.gov/33687470)\] 47. Stevens R, Macbeth F, Toy E, Coles B, Lester JF. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database Syst Rev. 2015 Jan 14;1(1):CD002143. \[[PMC free article: PMC7017846](/pmc/articles/PMC7017846/)\] \[[PubMed: 25586198](https://pubmed.ncbi.nlm.nih.gov/25586198)\] 48. Yang GM, Teo I, Neo SH, Tan D, Cheung YB. Pilot Randomized Phase II Trial of the Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer. Am J Hosp Palliat Care. 2018 Aug;35(8):1050-1056. \[[PubMed: 29409327](https://pubmed.ncbi.nlm.nih.gov/29409327)\] 49. Visentin A, Mantovani MF, Kalinke LP, Boller S, Sarquis LMM. Palliative therapy in adults with cancer: a cross-sectional study. Rev Bras Enferm. 2018 Mar-Apr;71(2):252-258. \[[PubMed: 29412280](https://pubmed.ncbi.nlm.nih.gov/29412280)\] 50. Soneji S, Yang J, Tanner NT, Silvestri GA. Occurrence of Discussion about Lung Cancer Screening Between Patients and Healthcare Providers in the USA, 2017. J Cancer Educ. 2020 Aug;35(4):678-681. \[[PubMed: 30852789](https://pubmed.ncbi.nlm.nih.gov/30852789)\] 51. Elia S, Loprete S, De Stefano A, Hardavella G. Does aggressive management of solitary